CEL-SCI Corp. (CVM) Building Shareholder Value, Using Perseverance and the Body’s Immune System to Fight Cancer
CEL-SCI Corp.’s (NYSE MKT: CVM) body of work with the human immune system is one of perseverance and a passion for survival despite odds that would make the vast majority of biotech companies fold their tents and choose easier endeavors. Faced with trending downturns in the biotech sector, limited funding, and an arduous clinical trial process connected with the development of its investigational therapy for advanced primary head and neck cancer, the company’s mission is now well within sight. CVM’s lead investigational immunotherapy, Multikine® (Leukocyte Interleukin, Injection), has been tested in Phase I and II clinical trials, and is now…